Question is, does the market share the view of our management. Also, the question is why havent US Investors picked up on the story. Remember, we even had a patient network taking sides in regards to the development of this Investigational Product. Any long term investor would pick up a high stake in shares given the low share price.
Any update from management in regards to feedback from institutional investors would be nice, a formal commitment even nicer.
Is there any progress of the email with questions to our CEO? We should ask what the current strategy is to drive the SP upwards.
NEU Price at posting:
$1.25 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)